Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication
Key facts
- Who runs it
- Jamil Cedeño Mora
- Where
- Spain12 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 1,200 people, planned
- Started
- 1 Oct 2025
- Expected to end
- 1 Jan 2028
- Type of study
- Observational
- Treatments tested
- Usage of vasopressin (VAP) as a second-line vasopressor in septic shock patients.
- Record updated
- 15 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Other criteria
- Eligible patients for this study must comply with the following requirements
- ICU admission with a septic shock diagnosis
- Age 18 years or above at ICU admission
- Use of vasopressin as an adjunct of norepinephrine; For the purposes of this study, septic shock is defined by full compliance with the following criteria
- Sustained arterial hypotension or serum lactate above 2 mmol/L
- Adequate but unsuccessful fluid resuscitation
- Vasopressor usage to maintain a mean arterial pressure above 65 mmHg
- Probable or proven infectious etiology; Patients with some of the following conditions will be automatically excluded
- Pregnancy
- Ischemic cardiogenic shock
- Acute intestinal ischemia
- Readmission to the Intensive Care Unit
This trial is currently available in Spain.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this observational study is to examine real-world clinical practice regarding the use of vasopressin as a second-line vasopressor in adult patients admitted to Intensive Care Units (ICUs) with septic shock.
Read full original descriptionShow less
The study focuses on critically ill adults (≥18 years) diagnosed with septic shock and treated with norepinephrine and vasopressin.
The main research questions are:
* Does early initiation of vasopressin-defined by the norepinephrine dose at the time of introduction-reduce mortality in patients with septic shock? * What is the impact of vasopressin as a second vasopressor on renal function and the progression of organ dysfunction in septic shock patients?
Participants will:
* Be admitted to an ICU with a diagnosis of septic shock. * Receive vasopressin as an adjunct to norepinephrine for hemodynamic support. * Be monitored daily throughout their ICU stay, with data collected through a dedicated REDCap system. * Have relevant clinical data pseudonymized and incorporated into the study database for statistical analysis.
Treatments tested
- Usage of vasopressin (VAP) as a second-line vasopressor in septic shock patients.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Use of Vasopressin in Septic Shock.
- Record updated
- 15 December 2025